Australasian Leukaemia & Lymphoma Group (ALLG)

At today's Chief Investigator Workshop, leading haematologists explored operational improvements, shared insights from current trials, and discussed practical approaches to trial planning, delivery and oversight. A valuable opportunity to support future trial success.

Keeping pace with progress in blood cancer research and care, Associate Members came together today to explore key updates across ALLG trials, the National Blood Cancer Registry and patient support processes - allg.org.au.

The ALLG Scientific Meeting is LIVE! Today's Haematology Education Day on myeloma brings together leading clinicians and researchers from across ANZ to share the latest advances in blood cancer research and treatment.

Tomorrow, we kick off the ALLG November Scientific Meeting with Haematology Education Day on Myeloma. Our Scientific Meetings bring together clinicians, researchers from across Australia & NZ to exchange ideas, that drive progress in blood cancer care - allg.org.au

Improving life after blood cancer treatment is the focus of a new ALLG HSANZ Clinical Trials Fellowship project. Dr Maxine Revoltar's 2027 Fellowship project will explore how the MyHodgkin MyHealth app can capture long-term survivorship data & generate real-world evidence.

ALLG members can register at allg.org.au for the ALLG November Scientific Meeting, 10-13 Nov in Melbourne. It's a great chance to hear about new trials, network and drive blood cancer research.

Congratulations to the CATER-HL ALLG HD12 investigators on a successful oral presentation at ISHL14. A significant advance for older and frail patients with Hodgkin lymphoma, demonstrating that potentially curative therapy can be both effective and well tolerated.

Join us in Melbourne from 10-13 November for four days of collaboration, scientific exchange and discussions shaping the future of blood cancer research. Hear from leading experts plus dedicated education and professional development opportunities for ALLG Associate Members.

ALLG's MDS05 MYDAS-T platform trial is advancing research into myelodysplastic syndromes (MDS), investigating innovative treatment approaches to improve outcomes and quality of life for people living with this rare blood cancer. Pictured: A/Prof Anoop Enjeti, Co-Chair of MDS

Are you an ALLG Associate Member? Join us at our November Scientific Meeting for dedicated Clinical Operations and Haematology Education Days. Explore the latest in clinical trial operations and current ALLG clinical trials.

Congratulations to Dr Maxine Revoltar, recipient of the 2027 ALLG HSANZ Clinical Trials Fellowship. Her project will explore integrating the MyHodgkin MyHealth app into Hodgkin lymphoma clinical trials to support long-term survivorship and patient-reported outcomes research.

Congratulations to all members presenting at #Blood2026. A huge congratulations to Dr Josh Tobin on completing his oral presentation for NHL31 Trebl-1. We're proud to see this important research shared with the global haematology community.

The countdown is on to ALLG's November Scientific Meeting. From 10–13 November at the Park Hyatt Melbourne, delegates will hear the latest research, trial updates and emerging developments in blood cancers from Australian and international speakers - allg.org.au.

This #Nationalcarersweek (11-17 Oct),we acknowledge the dedication, compassion and strength of carers supporting people living with blood cancer. Thank you for all that you do.

Looking forward to welcoming ALLG members to Melbourne for the 2026 Scientific Meeting 10-13 Nov. From clinical trial updates to emerging therapies & translational research, the program will showcase the latest developments shaping blood cancer treatment and care.

Registrations are open for the ALLG Scientific Meeting, 10–13 November at Park Hyatt Melbourne. Join leading clinicians and researchers as they share the latest advances in blood cancer research and clinical trials. Free for ALLG Members - allg.org.au.

As #BloodCancerAwarenessMonth comes to an end, our CEO reflects on the impact of clinical trials and the progress being made for people living with blood cancer.

This #WorldResearchDay, we're celebrating the researchers, clinicians and patients driving better outcomes in blood cancer. From transforming CML treatment to pioneering platform trials like AMLM26 and AMLM28, research continues to shape the future of care.

Research is continuing to advance outcomes in #CML. The ALLG CML14 ASCENDANCE trial is exploring a precision medicine approach using genomic markers and combination asciminib + low-dose dasatinib treatment for higher-risk newly diagnosed patients - allg.org.au.

Research saves lives. On #WorldALLDay, we're proud to recognise the impact of the ALL09 SUBLIME trial and the support that made it possible, including funding from Amgen and the Australian Government through an MRFF grant awarded via Canteen Australia. #ALL #ClinicalTrials